{"id":3833,"date":"2019-10-20T19:49:56","date_gmt":"2019-10-20T16:49:56","guid":{"rendered":"http:\/\/blog.ulubat.org\/?p=3833"},"modified":"2019-10-20T21:19:24","modified_gmt":"2019-10-20T18:19:24","slug":"farkli-dokularin-antijenleriyiz-hla-dunyasi-2","status":"publish","type":"post","link":"https:\/\/blog.ulubat.org\/index.php\/genel\/farkli-dokularin-antijenleriyiz-hla-dunyasi-2\/","title":{"rendered":"FARKLI DOKULARIN ANT\u0130JENLER\u0130Y\u0130Z : HLA D\u00dcNYASI"},"content":{"rendered":"\n<ul class=\"wp-container-2 wp-block-gallery-1 wp-block-gallery columns-1 is-cropped\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1024x1024.png\" alt=\"\" data-id=\"3834\" data-link=\"https:\/\/blog.ulubat.org\/?attachment_id=3834\" class=\"wp-image-3834\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1024x1024.png 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-150x150.png 150w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-125x125.png 125w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-110x110.png 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-420x420.png 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-400x400.png 400w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-768x768.png 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><a href=\"https:\/\/www.mskcc.org\/cancer-care\/patient-education\/human-leukocyte-antigen-typing\">https:\/\/www.mskcc.org\/cancer-care\/patient-education\/human-leukocyte-antigen-typing<\/a><\/figcaption><\/figure><\/li><\/ul>\n\n\n\n<p><br><\/p>\n\n\n\n<p>Kan gruplar\u0131, k\u0131rm\u0131z\u0131 k\u00fcreler \u00fczerindeki antijenler  ile belirlenir. Bunlara benzer \u015fekilde akyuvarlar \u00fczerinde de her bir insanda  HLA ad\u0131 verilen antijenler bulunur. Bir nevi kimlik kart\u0131m\u0131z\u0131 olu\u015ftururan HLA&#8217;lar\u0131n say\u0131s\u0131 ve \u00e7e\u015fidi olduk\u00e7a fazlad\u0131r. HLA&#8217; lar farkl\u0131 kombinasyonlarda ve say\u0131larda bulunarak doku tipimizi olu\u015fturur. HLA proteinleri  v\u00fccudumuzdaki bir\u00e7ok h\u00fccrede bulunmaktad\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sisteminiz bu belirte\u00e7leri hangi h\u00fccrelerin sizin v\u00fccudunuza ait oldu\u011funu hangilerinin olmad\u0131\u011f\u0131n\u0131 ay\u0131rt etmek i\u00e7in kullan\u0131r. HLA&#8217;lar klinikte temel olarak  transplantasyon\/transf\u00fczyon, HLA polimorfizm \u00e7e\u015fitlerine g\u00f6re hastal\u0131k yatk\u0131nl\u0131klar\u0131n\u0131n incelenmesi ve babal\u0131k testi <br> amac\u0131yla kullan\u0131lmaktad\u0131r. Biz bu yaz\u0131da HLA&#8217;lar\u0131 \u00f6nce daha yak\u0131ndan tan\u0131yacak sonra da  transplantasyon\/transf\u00fczyon a\u015famas\u0131ndaki \u00f6nemini vurgulayaca\u011f\u0131z.<\/p>\n\n\n\n<p><strong>HLA NED\u0130R, NASIL KE\u015eFED\u0130LD\u0130 ?<\/strong><br> Bilim insanlar\u0131 ki\u015fiden ki\u015fiye kan transf\u00fczyonu yap\u0131l\u0131rken bir reaksiyonun olmamas\u0131n\u0131n, al\u0131c\u0131 ve verici aras\u0131nda kan grubu uygunlu\u011funu\u00a0 gerektirmesi d\u00fc\u015f\u00fcncesinden hareketle, doku ve organ transplantasyonlar\u0131 i\u00e7in de h\u00fccrelerin y\u00fczey antijenleri bak\u0131m\u0131ndan uygun olmas\u0131 gerekti\u011fini d\u00fc\u015f\u00fcnm\u00fc\u015fler ve bu konudaki \u00e7al\u0131\u015fmalar sonucunda HLA sistemini ke\u015ffetmi\u015flerdir.<\/p>\n\n\n\n<p>1944 y\u0131l\u0131nda ara\u015ft\u0131rmac\u0131lar, tav\u015fanlar \u00fczerinde yapt\u0131klar\u0131 deneylerde, organ transplantasyonunda g\u00f6r\u00fclen reaksiyonlar\u0131n imm\u00fcnolojik bir temele dayal\u0131 oldu\u011funu g\u00f6stermi\u015flerdir. Takip eden \u00e7al\u0131\u015fmalarda, ilk kez insan l\u00f6kositlerinde doku uygunluk antijenlerini g\u00f6stermeyi ba\u015farm\u0131\u015flard\u0131r. Baz\u0131 ara\u015ft\u0131rmac\u0131lar da kan transf\u00fczyonu yap\u0131lm\u0131\u015f ki\u015filerin serumlar\u0131nda l\u00f6kositlere kar\u015f\u0131 geli\u015fmi\u015f antikorlar\u0131n Bulundu\u011funu kan\u0131tlam\u0131\u015flar, yap\u0131lan g\u00f6zlemlerle kendilerine kar\u015f\u0131 antikor geli\u015fen antijenlerin sadece L\u00f6kositlerde de\u011fil, doku h\u00fccrelerinde de bulundu\u011funu g\u00f6stermi\u015flerdir. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-1024x1024.png\" alt=\"\" class=\"wp-image-3836\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-1024x1024.png 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-150x150.png 150w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-250x250.png 250w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-125x125.png 125w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-110x110.png 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-420x420.png 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-1-768x768.png 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Bu antijenler \u201cDoku Uygunluk Antijenleri\u201d veya \u201cTransplantasyon Antijenleri\u201d olarak isimlendirilmi\u015ftir. 1967\u2019de bu antijenlerin isimlendirilmesinde g\u00f6r\u00fc\u015f birli\u011fine var\u0131larak ilk Kez l\u00f6kositlerde g\u00f6sterilmi\u015f olmalar\u0131ndan dolay\u0131 \u201c\u0130nsan L\u00f6kosit Antijenleri\u201d anlam\u0131na gelen \u201cHLA: Human Leukocyte Antigens\u201d k\u0131saltmas\u0131 kullan\u0131lmaya ba\u015flanm\u0131\u015ft\u0131r. Burada HLA&#8217;lar\u0131n isminden yola \u00e7\u0131karak sadece l\u00f6kositlerde bulundu\u011fu d\u00fc\u015f\u00fcncesinin yanl\u0131\u015f oldu\u011fu dikkat edilmesi gereken temel noktad\u0131r.<\/p>\n\n\n\n<p><strong>HLA ANT\u0130JENLER\u0130N\u0130N OLU\u015eMA MEKAN\u0130ZMASI ve HLA \u00c7E\u015e\u0130TL\u0130L\u0130\u011e\u0130<\/strong><br> HLA antijenlerinin olu\u015fmas\u0131 organizmada  <br> \u201cMaj\u00f6r Histokompatibilite kompleksi-Major  <br> Histocompatibility Complex Gen Region (MHC)\u201d  ad\u0131 verilen bir gen b\u00f6lgesinin kontrol\u00fc alt\u0131ndad\u0131r.  \u0130nsanlarda bu gen b\u00f6lgesi 6 numaral\u0131 kromozomun k\u0131sa kolu \u00fczerinde yer almakta ve kromozom haritas\u0131nda p21 pozisyonunda g\u00f6sterilmektedir. Genellikle MHC sistemine \u00f6zg\u00fc olmak \u00fczere kromozom \u00fczerinde bulunan genleri ifade etmek i\u00e7in haplotip terimi kullan\u0131lmaktad\u0131r. Haplotip terimi, bir kromozom \u00fczerinde \u00e7ok yak\u0131n ba\u011flant\u0131 g\u00f6steren ve dolay\u0131s\u0131yla bir birim halinde kal\u0131t\u0131lan Bir gen grubuna verilen add\u0131r. <br>HLA genleri kodominantt\u0131r, hem anne hem de baba 2 haplotip ta\u015f\u0131r ve bunlardan herhangi birini \u00e7ocuklar\u0131na verebilir. Haplotiplerin kal\u0131t\u0131m\u0131 Mendel yasalar\u0131na g\u00f6redir. HLA genleri polimorfik olup haplotip olas\u0131l\u0131\u011f\u0131 y\u00fcksektir.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-1024x1024.jpg\" alt=\"\" class=\"wp-image-3837\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-1024x1024.jpg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-150x150.jpg 150w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-249x250.jpg 249w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-125x125.jpg 125w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-110x110.jpg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/Hu_MHCchrom6-768x768.jpg 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>MHC gen b\u00f6lgesinin her lokusunda her biri farkl\u0131 HLA antijenlerinden sorumlu allel genler bulunur. HLA allelleri ve \u00fcr\u00fcnleri HLA antijeni olarak ifade edilirler. HLA antijenleri mobildirler. H\u00fccre y\u00fczeyinden kopup yeniden sentezlenebilirler. MHC gen b\u00f6lgesi 3 ana gruba ayr\u0131lmaktad\u0131r:<br> \u2022MHC S\u0131n\u0131f-I (HLA-A, -B, -C,-E, -F, -G), <br> \u2022MHC S\u0131n\u0131f-II (HLA-DR, -DP, -DQ, -DO, -DN) <br> \u2022MHC S\u0131n\u0131f-III (C2, C4A, C4B, PF, TNF-\u03b1,\u03b2) antijenleri yer almaktad\u0131r. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" width=\"1024\" height=\"941\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-1024x941.jpg\" alt=\"\" class=\"wp-image-3838\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-1024x941.jpg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-400x368.jpg 400w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-768x706.jpg 768w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-110x101.jpg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-420x386.jpg 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621-468x430.jpg 468w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/IMG_20191020_182621.jpg 1050w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>HLA-A,-B,-C; klasik S\u0131n\u0131f-I antijenleridir, hemen her dokuda eksprese olurlar, fonksiyonlar\u0131 daha bilinmektedir. <br>HLA-E,-F,-G non-klasik S\u0131n\u0131f-I antijenleridir, daha az say\u0131da dokuda eksprese olurlar. <br>HLA-G\u2019nin sadece plasental dokuda eksprese oldu\u011fu ve fonksiyonunun fet\u00fcs\u00fcn canl\u0131l\u0131\u011f\u0131 ile ilgili oldu\u011fu san\u0131lmaktad\u0131r. <br> MHC S\u0131n\u0131f-II antijenlerinden HLA-DR,-DP ve DQ klasik S\u0131n\u0131f-II antijenleridir. Daha fazla dokuda eksprese olup, fonksiyonlar\u0131 hakk\u0131nda daha fazla bilgi mevcuttur.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>TRANSPLANTASYON\/TRANSF\u00dcZYONDA HLA&#8217;LARIN \u00d6NEM\u0130<\/strong><\/p>\n\n\n\n<p>Do\u011fru bilinen yanl\u0131\u015flardan biri de organ nakillerinde doku uyumunun zorunlu oldu\u011fu d\u00fc\u015f\u00fcncesidir. San\u0131ld\u0131\u011f\u0131n\u0131n aksine doku uyumu tercih edilmekle birlikte, organ naklinde \u015fart de\u011fildir. Doku uyumundan daha \u00e7ok, doku uyumsuzlu\u011funun olup olmad\u0131\u011f\u0131 incelenmekte ve transplantasyon vakalar\u0131nda bu konu ele al\u0131nmaktad\u0131r.<br> Transplantasyonda HLA -A,-B,-DR antijenlerindeki uyumun \u00f6nemini kan\u0131tlayan pek \u00e7ok \u00e7al\u0131\u015fma vard\u0131r. HLA -C ve HLA-DQ i\u00e7in de benzer yay\u0131nlar bulunsa da bu iki grubun s\u0131ras\u0131 ile -B ve -DR antijenleri ile g\u00f6sterdikleri birliktelikler (linkeage disequlibrium) objektif bir de\u011ferlendirmeyi g\u00fc\u00e7le\u015ftirmektedir. B\u00f6brek nakillerinde graft ya\u015fam\u0131nda HLA-DR uyumunun HLA -B ve -A uyumundan daha belirleyici oldu\u011fu, Pankreas nakillerinde de HLA-DR uyumunun \u00f6n planda oldu\u011fu g\u00f6r\u00fcl\u00fcrken; karaci\u011fer nakillerinde HLA uyumunun \u00f6nemi hakk\u0131nda farkl\u0131 g\u00f6r\u00fc\u015fler vard\u0131r. HLA uyumunun graft ya\u015fam\u0131n\u0131 k\u0131saltabildi\u011fi, etkisinin olmad\u0131\u011f\u0131, HLA-A <br> ve -B uyumunun olumlu etkileri varken HLA-DR uyumunun etkisi olmad\u0131\u011f\u0131 y\u00f6n\u00fcnde yay\u0131nlar vard\u0131r. Kalp nakillerinde de uyumsuz antijen say\u0131s\u0131 azald\u0131k\u00e7a graft \u00f6mr\u00fcn\u00fcn uzad\u0131\u011f\u0131na dair \u00e7al\u0131\u015fmalar bulunmakta olup HLA-DR nin daha \u00f6nemli olabilece\u011fi vurgulanmaktad\u0131r. Kornea nakillerinde HL-A, -B uyumu \u00f6nemli bulunurken HLA-DR hakk\u0131nda farkl\u0131 g\u00f6r\u00fc\u015fler vard\u0131r. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-1024x1024.jpeg\" alt=\"\" class=\"wp-image-3839\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-1024x1024.jpeg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-150x150.jpeg 150w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-250x250.jpeg 250w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-125x125.jpeg 125w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-110x110.jpeg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2019\/10\/images-8-768x768.jpeg 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Hematopoetik k\u00f6k h\u00fccre nakillerinde ise tek haplotip uyumu ile (haploidentik) nakil uygulamalar\u0131 ba\u015flam\u0131\u015f olsa bile halen hedeflenen tam uyum g\u00f6steren bir vericinin kullan\u0131lmas\u0131d\u0131r.<\/p>\n\n\n\n<p>Kemik ili\u011fi nakillerinde ise al\u0131c\u0131 ve verici aras\u0131ndaki doku uyumu \u00e7ok m\u00fchimdir. HLA antijenleri al\u0131c\u0131 ve verici aras\u0131ndaki uyumlulu\u011funa (8\/8 veya 10\/10: tam uyum; 7\/8 veya 9\/10: iyi uyum; 5\/10-8\/10: haploidantik; kordon kanlar\u0131 i\u00e7in 4-6\/6 uyum yeterlidir) g\u00f6re de\u011ferlendirilerek nakil s\u00fcrecinde ilerleme katedilir.<\/p>\n\n\n\n<p>HLA d\u00fcnyas\u0131 tam olarak ayd\u0131nlat\u0131lamam\u0131\u015f olup bu konuda \u00e7al\u0131\u015fmalar s\u00fcrmektedir. Doku antijenlerini tam olarak kavrad\u0131\u011f\u0131m\u0131zda organ nakilleri \u00fczerindeki etkilerini daha detayl\u0131 bir \u015fekilde g\u00f6zlemleyebilece\u011fiz. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Kaynak\u00e7a:<\/p>\n\n\n\n<ul><li>K\u0131l\u0131\u00e7turgay K. Maj\u00f6r histokompatibilite kompleksi. \u0130mm\u00fcnolojiye Giri\u015f. 3. Bask\u0131. \u0130stanbul: G\u00fcne\u015f ve Nobel T\u0131p Yay\u0131nevi; 1994. p.33-40.<\/li><li>Schwartz BD. The human major histocompatibility HLA complex. In: Stites DP, Stobo JD, Wells JV, eds. Basic and Clinical Immunology. 6th ed. California: Appleton and Lange; 1987. p.50-64.<\/li><li>Kuby J. Major histocompatibility complex.Immunology 3th ed. New York: Van Hoffman Press; 1997. p.223-48.<br><\/li><li>O\u011fuz FS, \u00c7arin M. MHC genlerinin organizasyonu. Send-om 1999;11:126-7.<\/li><li>Bodmer WF, Albert ED, Bodmer JG. Nomenclature for factors of HLA system. Tissue Antigens 1984;24:73-80.<\/li><li>Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA, system, 1998. Tissue Antigens 1999;53(4 Pt 2):407-6.<\/li><li>Albert ED, Bodmer WF, Bontrop RE, et al. Nomenclature for factors of the HLA system. Tissue Antigens 2002;60:407-64.<\/li><li>G\u00fclmezo\u011flu E, Erg\u00fcven S. Doku uygunluk antijenleri. \u0130mm\u00fcnoloji. Ankara: Hacettepe-Ta\u015f Kitap\u00e7\u0131l\u0131k; 1994. p.29-40.<br>Ba\u015faran N. T\u0131bbi Genetik. 6. Bask\u0131. Eski\u015fehir: Bilim Teknik Kitabevi; 1996. p.320-52.<\/li><li>Dick HM. HLA and disease. Br Med Bull 1978;34:271-4.<\/li><li>Hill AV. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.<\/li><li>Zavaglia C, Bortolon C, Ferrioli G, et al. HLA typing in chronic type B, D and C hepatitis. J Hepatol 1996;24<\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Kan gruplar\u0131, k\u0131rm\u0131z\u0131 k\u00fcreler \u00fczerindeki antijenler ile belirlenir. Bunlara benzer \u015fekilde akyuvarlar \u00fczerinde de her bir insanda HLA ad\u0131 verilen<\/p>\n","protected":false},"author":201,"featured_media":3835,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"acf":[],"views":1837,"_links":{"self":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/3833"}],"collection":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/users\/201"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/comments?post=3833"}],"version-history":[{"count":7,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/3833\/revisions"}],"predecessor-version":[{"id":3860,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/3833\/revisions\/3860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/media\/3835"}],"wp:attachment":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/media?parent=3833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/categories?post=3833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/tags?post=3833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}